You are currently browsing articles tagged APAP.

According to a new report by iData Research, the leading global authority in medical device market research, the European anesthesia, respiratory and sleep-management device market was valued at over $1.4 billion in 2011. By 2017, this market is expected to reach almost $2 billion, fueled by the rapidly growing telehealth/homecare therapeutic sleep-apnea and ventilator segments. Philips Respironics, ResMed and CareFusion are leading these markets, despite growing competition.

“Sleep disorders are becoming much more widely diagnosed in Europe, which is driving the demand for more advanced devices that can diagnose, treat and monitor in the home,” says Dr. Kamran Zamanian, CEO of iData. “Philips, ResMed and CareFusion are leaders in this space, however many other companies have released products in a bid to gain share in this lucrative market.”

The report states that the market for automatic positive airway-pressure (APAP) devices, which automatically detect apneic events, are expected to be the fastest-growing segment. The U.K. and France are leading in sales growth, however there is expected to be a dramatic increase in demand in Germany, Spain and Austria.

Additionally, the ventilator segment is expected to see strong growth fueled by increased sub-acute and homecare usage as well as new remote-monitoring ventilators. Philips narrowly leads this market with their non-invasive homecare ventilators, but faces strong competition from ResMed.


Tags: , , , , , , , , ,